Sign In
Buy RCKT
$2.92
+0.0300 (+1.04%)
At Close: Jun 03, 2026
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
04:01pm, Thursday, 27'th Feb 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharma Is A Buy At These Prices With Promising Data
03:40pm, Wednesday, 12'th Feb 2025
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 15'th Jan 2025
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
04:00pm, Thursday, 02'nd Jan 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
03:00pm, Wednesday, 18'th Dec 2024
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeli
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 10'th Dec 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
3 Small-Cap Stocks That Are Ready to Rocket Higher
08:06am, Wednesday, 27'th Nov 2024
The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
07:00am, Tuesday, 26'th Nov 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
02:47pm, Tuesday, 19'th Nov 2024
On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
11:10am, Monday, 11'th Nov 2024
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank
09:11am, Monday, 11'th Nov 2024
Scotiabank raised the firm's price target on Rocket Pharmaceuticals to $51 from $50 and keeps an Outperform rating on the shares. The company provided "a slew of positive updates," which included an a
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
07:00am, Friday, 08'th Nov 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
03:18pm, Thursday, 19'th Sep 2024
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accel
